194 Influence of Montelukast on the State of Eosinophil Activation in Asthmatic Children

increased the time to first asthma deterioration thus decreasing the proportion of subjects experiencing asthma deterioration during the study (MF/F 1⁄4 16.5%; versus MF 1⁄4 28.2% [P 1⁄4 0.006]; versus F 1⁄4 44.7% [P , 0.001]; and vs placebo 1⁄4 45.7% [P , 0.001]). Mean FEV1 AUC0–12h over baseline at week 12 were MF/F 1⁄4 4.00 L · h; MF 1⁄4 2.53 L · h; F 1⁄4 3.83 L · h; and placebo 1⁄4 1.11 L · h. Low rates of AEs were observed and were similar between treatment arms. Conclusions: In asthmatics previously treated with low-dose ICS with or without a LABA, MF/F 100/10 mg BID was more effective than placebo, MF, or F (all administered by MDI) in reducing asthma deteriorations and improving lung function.